Vaccine Indicated Articles & Analysis
17 news found
By doing so we’ll improve our ability to create new biologics from natural proteins, and bring new therapeutics to patients across a wide range of indications from infectious disease vaccines and therapeutics, to rheumatology, to rare disease, and to autoimmune disorders. ...
“We are excited about the potential of our HD-MAP vaccine patch technology to change the way vital vaccines are delivered both locally and on a global scale,” said Dr Forster. ...
About Scancell Scancell is developing novel immunotherapies for the treatment of cancer based on its technology platforms, ImmunoBody®, Moditope® and AvidiMabTM, with four products in multiple cancer indications, development of a vaccine for COVID-19 and a growing portfolio of novel anti-TaG monoclonal antibodies. ImmunoBody® ...
ByScancell
If VOLT elects not to exercise its option, Cancer Research UK will have the right to take the programme forward in all cancer indications. Unlike preventative vaccines, such as the influenza vaccine, which is given to healthy people to protect them against future disease, VTP-600 is given to people who already have lung cancer. ...
The approval indicates the vaccine production is at a high standard which will help to secure timely patient access to vaccines in the Gulf Cooperation Council (GCC) countries and wider Middle Eastern region. ...
Abera Bioscience AB (“Abera” or “the Company”) continues to improve its vaccine platform in collaboration with researchers at Vrije Universiteit Amsterdam. ...
Since the discovery of RSV in 1956, no vaccine has been approved for prevention. “We believe that our intranasal live attenuated RSV vaccine candidate, developed on Meissa’s AttenuBlockTM vaccine platform, offers the potential to finally immunize against RSV, which has evaded other vaccine technologies for ...
A COVID-19 vaccine candidate developed by a UB spinoff company has progressed to human trials in South Korea, according to a UBNow story. ...
Meissa is developing MV-012-968, an intranasal (needle-free), live attenuated vaccine candidate, to protect infants and at-risk, older adults from RSV. ...
Furthermore, building our COVID-19 vaccine candidate on our RSV vaccine platform provides safety advantages compared to a live attenuated coronavirus ...
International vaccine manufacturer, AJ Vaccines has received WHO prequalification for Picovax®, the first stand-alone dose sparing Inactivated Polio Vaccine (IPV) on 21st April 2020. ...
Evidence indicates the current vaccine may cause acute side effects, as well as the risk of potential fetal harm if administered to pregnant women. “The BlueWillow/PBL anthrax vaccine has the potential to provide significant advantages over the current injectable vaccine,” said BlueWillow CEO Dave Peralta. ...
This evaluation has proven the ability of IMX313P to enhance the efficacy of a DKFZ’ vaccine candidate indicated in the prevention of human papillomavirus (HPV) infections, a virus that can lead to cervical cancers. DKFZ has therefore decided to exercise its option right, and to move forward in the development of this IMX313P-based vaccine ...
Thanks to this deal, Imaxio will now focus on the commercialization of Spirolept®, its human vaccine indicated for the prevention of a professional infectious disease, and on the development of its vaccines pipeline, based on its proprietary technology IMX313. IMX313 is an antigen re-engineering pro-immunogenic technology which significantly ...
Imaxio, a biotech company specialising in immunology, announces today the execution of a license agreement with AJ Biologics, a Malaysian company dedicated to vaccine manufacturing and commercialization, as part of the company’s strategy to extend the distribution of Imaxio’s leptospirosis vaccine in Malaysia. Imaxio is a French SME developing an ...
Submitted in 2012 and 2013, and respectively entitled “Modified coiled-coil type proteins having improved properties” and “Influenza nucleoprotein vaccines”, these two patents offer additional cover on the American market to the new generation of Imaxio’s antigen re-engineering technology, as well as to its influenza vaccine ...
It will be tested to enhance the efficacy of one of the Center’s candidate vaccines, which is indicated in the prevention of human papillomavirus (HPV) infections. ...